ArchPoint Investors’s Novo Nordisk NVO Stock Holding History

ArchPoint Investors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,466	Closed	-$262K	–	109
2021 Q3	$262K	Buy	+5,466	New	+$264K	0.08%	83

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ArchPoint Investors's NVO Position: Q4 2021 in Review

ArchPoint Investors sold out of Novo Nordisk (NVO) in Q4 2021, closing a stake of 5,466 shares — an estimated $262K sold.

ArchPoint Investors first reported a position in NVO in Q3 2021 and held it in 1 quarter. The position peaked at $262K in Q3 2021. 886 funds tracked by Wall St. Rank hold NVO as of Q4 2021.

ArchPoint Investors reported no remaining Novo Nordisk position as of Q4 2021 after selling out during the quarter.
ArchPoint Investors sold 5,466 Novo Nordisk shares in Q4 2021, an estimated $262K.
ArchPoint Investors first reported a position in Novo Nordisk in Q3 2021 and held it in 1 quarter.
ArchPoint Investors's Novo Nordisk position peaked at $262K in Q3 2021.
886 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2021.

Based on ArchPoint Investors's 13F filing for Q4 2021, filed 11 Feb 2022.